{"chunk":"AUDIT REPORT\n11-12 APRIL 2024\nThis report was prepared by Todd Buchheit of cGMP Validation and\ncontains the observations and recommendations made during a mock\ninspection conducted on 11-12 of the Mark Cuban Cost Plus Drug\nCompany, located at 320 S. Walton Street Dallas, TX.\nTABLE OF CONTENTS\nContents","book":"internal_audit_report_2024"}
{"chunk":"Contents\nAudit Summary __________________________________________________________________________________________ 1\nDetails of the Audit ______________________________________________________________________________________ 3\nFindings___________________________________________________________________________________________________ 5","book":"internal_audit_report_2024"}
{"chunk":"Recommendations for Improvement ___________________________________________________________________ 9\nSummary ________________________________________________________________________________________________ 12\nAuditor\u2019s Contact Information _________________________________________________________________________ 13","book":"internal_audit_report_2024"}
{"chunk":"Company Information __________________________________________________________________________________ 13\nAUDIT SUMMARY\nAudit Summary\nGENERAL OVERVIEW\ncGMP Validation was contracted for the purpose of conducting a Mock FDA inspection of\nthe Quality Management System to determine if the activities performed there were","book":"internal_audit_report_2024"}
{"chunk":"compliant with 21 CFR Part 211 and 503b FDA Guidance for Human Drug Compounding\nOutsource Facilities. The audit was a two-day assessment which consisted of a facility\ntour, process flow walk-throughs, reviewing documentation, and interviewing employees\nto gain an understanding of how the facility operates and how well they are compliant","book":"internal_audit_report_2024"}
{"chunk":"with the FDA regulation and their established SOPs.\nIn this report you will find:\n\uf0b7 A full list of the systems reviewed.\n\uf0b7 A list of findings (Observations, Concerns and Opportunities for Improvement).\n\uf0b7 Recommendations for improvement.\nOnly areas where observations were noted are discussed in detail.\nSUMMARY OF THE VISIT","book":"internal_audit_report_2024"}
{"chunk":"Two days were spent conducting the audit. The primary point of contact during the\nassessment was Matthew Callesen, Head of Quality and Allyson Koger, Production\nSupervisor. Matthew is identified in the organizational chart as having QA responsibility.\nAll participants were very professional throughout the audit and very knowledgeable","book":"internal_audit_report_2024"}
{"chunk":"about the operations at the Dallas facility. I would like to acknowledge the others who\nparticipated as their assistance was greatly appreciated and helpful in completing the\naudit, they are as follows:\n\uf0b7 Hasham Altaf \u2013 Production Supervisor\n\uf0b7 Daniel Royster \u2013 Director of Manufacturing Facilities Supply Chain\n\uf0b7 Mary Policronis \u2013 Quality Manager","book":"internal_audit_report_2024"}
{"chunk":"\uf0b7 Carvey Patterson \u2013 QC Manager\n\uf0b7 Thinh Tran \u2013 Senior Manager Facility Maintenance\n\uf0b7 Benjamin Russell \u2013 Facility Engineer\n\uf0b7 Bradley Stock \u2013 Engineering and Validation Manager\n\uf0b7 Chris Deitz \u2013 VP of Facilities and Engineering\n\uf0b7 David Walter \u2013 Senior Manager of Automation\nPage 1\nAUDIT SUMMARY\n\uf0b7 Andrew Nunez \u2013 Senior Process Engineer","book":"internal_audit_report_2024"}
{"chunk":"The full agenda was completed, and the facility tour was comprehensive. My overall\nimpression at the end of the audit was that the quality system is appropriate for the size\nof the organization and type of operations conducted. During the audit there were\nseveral issues noted that the organization should consider addressing as soon as","book":"internal_audit_report_2024"}
{"chunk":"possible. These are discussed in detail in the next section of this report.\nPage 2\nDETAILS OF THE AUDIT\nDetails of the Audit\nThe following areas of the Quality System were reviewed during the audit:\n\uf0b7 Quality Assurance Activities\no Responsibilities of QA\no Personnel qualifications\no personnel responsibilities\no consultants\n\uf0b7 Facility Design","book":"internal_audit_report_2024"}
{"chunk":"\uf0b7 Facility Design\no Design and construction features\no Environmental Controls (Ventilation, air filtration, heating and cooling)\no Preventative Maintenance Program\n\uf0b7 Control Systems and Procedures for Maintaining Suitable Facilities\no Building Management Systems\no Equipment Monitoring Systems\n\uf0b7 Personnel Monitoring\n\uf0b7 Equipment","book":"internal_audit_report_2024"}
{"chunk":"\uf0b7 Equipment\no Design, size and location\no equipment construction\no cleaning and maintenance\no automatic, mechanical, and electronic equipment\no filters\n\uf0b7 Containers and Closures\no Receipt and storage of untested components, drug product containers, and closures\no testing and approval or rejection of components, drug product containers, enclosures","book":"internal_audit_report_2024"}
{"chunk":"o use of approved components, drug product containers, and closures\no rejected components, drug product containers and closures\n\uf0b7 Components (503b guidance)\no Component Supplier Qualification Testing\no Testing for Finished Product to Be Used as a Source Material for Processing\n\uf0b7 Production and Process Controls\no Written procedures and deviations","book":"internal_audit_report_2024"}
{"chunk":"o charge in of components\no calculated yield\no equipment identification\no sampling and testing of in process materials and drug products\no time limitations on production\no control of microbial contamination\no reprocessing\n\uf0b7 Release Testing\n\uf0b7 Laboratory Controls\no Testing and release for distribution\no special testing requirements\nPage 3","book":"internal_audit_report_2024"}
{"chunk":"Page 3\nDETAILS OF THE AUDIT\no reserve samples\n\uf0b7 Stability Testing\/Expiration Dating for Compounded Drug Products\no Stability Program and Beyond-Use Dating\no Establishing an In-Use Time for Sterile Drug Products\no In-Use Time and BUDs for Sterile Drug Products\n\uf0b7 Packaging and Labels\no Materials examination and usage criteria\no labeling issuance","book":"internal_audit_report_2024"}
{"chunk":"o labeling issuance\no packaging and labeling operations\no tamper evident packaging requirements for OTC products\no drug product inspection\no expiration dating\n\uf0b7 Holding and distribution\no Warehouse procedures\no Distribution procedures\n\uf0b7 Reserve Samples\n\uf0b7 records and reports\no Equipment cleaning and use logs","book":"internal_audit_report_2024"}
{"chunk":"o Component, drug product container, closure, and labeling records\no Master production and control records\no Batch production and control records\no Production record review\no Laboratory records\no Distribution records\no Complete files\nPage 4\nFINDINGS\nFindings\nFindings are classified using the following criteria:\nObservation (Major):","book":"internal_audit_report_2024"}
{"chunk":"\uf0b7 A condition which, if discovered by regulatory authorities such as the FDA, would\nbe considered a violation of the regulation and could result in the issuance of a\n483 observation.\n\uf0b7 A condition which may make a product unfit for use and likely to present a risk to\nthe user.\nObservation (Minor):","book":"internal_audit_report_2024"}
{"chunk":"\uf0b7 A condition, if uncorrected, might be cited by regulatory authorities as a violation\nof the regulation.\n\uf0b7 Isolated issues that if not corrected, would not cause risk to the user or product,\nbut are a deviation from GMPs.\n\uf0b7 Significant numbers of minor findings in one system, which are indicative of a\nsystemic failure.","book":"internal_audit_report_2024"}
{"chunk":"systemic failure.\nOpportunity For Improvement:\n\uf0b7 Suggestions, if implemented, will contribute to a higher level of compliance, and\nensure better alignment with GMPs.\nPage 5\nFINDINGS\nLABELING\nObservation 1 (Major).\n211.125 Labeling Issuance:\n(a)Strict control shall be exercised over labeling issued for use in drug product\nlabeling operations.","book":"internal_audit_report_2024"}
{"chunk":"(b) Labeling materials issued for a batch shall be carefully examined for identity\nand conformity to the labeling specified in the master or batch production\nrecords.\n(c) Procedures shall be used to reconcile the quantities of labeling issued, used,\nand returned, and shall require evaluation of discrepancies found between the","book":"internal_audit_report_2024"}
{"chunk":"quantity of drug product finished and the quantity of labeling issued when such\ndiscrepancies are outside narrow preset limits based on historical operating\ndata.\nWhile reviewing how labels are stored at the facility the investigator was shown the\nstorage room where the labels are kept. While in the storage room, the investigator","book":"internal_audit_report_2024"}
{"chunk":"noticed a label counting device. When asked what its purpose was, it was pointed out\nthat this was the device that was used for issuing labels. Its specific purpose was to\ncount the number of labels that were being issued for a production work order.\nWhen the investigator asked if the label counter was validated, the answer was no.","book":"internal_audit_report_2024"}
{"chunk":"(f) Procedures shall be written describing in sufficient detail the control\nprocedures employed for the issuance of labeling; such written procedures shall\nbe followed.\nWhen entering the labeling room, the investigator noticed that badge access was\nrequired. The question was asked who was authorized to enter the labeling room","book":"internal_audit_report_2024"}
{"chunk":"period specifically who had badge access to the area. It was not known at that\nparticular moment, however QA staff provided a list from the security system\nsoftware that showed nearly everyone in the facility had access to the room.\nPage 6\nFINDINGS\nVENDOR QUALIFICATIONS\nObservation 2 (Major).","book":"internal_audit_report_2024"}
{"chunk":"Subpart E - Control of Components and Drug Product Containers and Closures\nSec. 211.80 General requirements.\n(a) There shall be written procedures describing in sufficient detail the receipt,\nidentification, storage, handling, sampling, testing, and approval or rejection of","book":"internal_audit_report_2024"}
{"chunk":"components and drug product containers and closures; such written procedures\nshall be followed.\nWhile reviewing the vendor qualification SOP, it was not clear how vendors are\ncategorized according to criticality. Looking at the approved suppliers list, an\nexamination of the vendor who supplies vials was made to determine if they were","book":"internal_audit_report_2024"}
{"chunk":"qualified according to the SOP. A review of the file indicated that the vendor should\nbe qualified by performing an audit. The record showed that the vial supplier had not\nbeen audited, and that the vials were accepted on a COA. This was also true for other\nvendors who were considered critical suppliers.\nRECORDS AND REPORTS\nObservation 3 (Minor).","book":"internal_audit_report_2024"}
{"chunk":"Sec. 211.186 Master production and control records.\n(b) Master production and control records shall include:\n(9) Complete manufacturing and control instructions, sampling and testing\nprocedures, specifications, special notations, and precautions to be followed.\nIn the mixing section of the master batch record the settings for the mixer had only","book":"internal_audit_report_2024"}
{"chunk":"the lower RPM limit setting for the mixer, but not an upper RPM limit setting.\nEquipment settings listed in the master batch record should contain the full operating\nrange that is allowed to be set by the operator. This range normally comes from the\nequipment validation records.\nPage 7\nFINDINGS\nFACILITIES\nObservation 4 (Minor).","book":"internal_audit_report_2024"}
{"chunk":"211.56 Sanitation: Any building used in the manufacture, processing, packing, or\nholding of a drug product shall be maintained in a clean and sanitary condition,\nAny such building shall be free of infestation by rodents, birds, insects, and other\nvermin (other than laboratory animals).","book":"internal_audit_report_2024"}
{"chunk":"During the facility tour the investigator noticed the absence of insect light traps\naround the delivery doctors. Insect light traps are in an integral part of a pest control\nprogram and are key in controlling the intrusion of flying insects.\nPage 8\nRECOMMENDATIONS FOR IMPROVEMENT\nRecommendations for Improvement\nObservation 1 (Major).\nLabeling","book":"internal_audit_report_2024"}
{"chunk":"Labeling\nThe label counting machine that we looked at needs to be validated. It can be a simple PQ\nwhere you run three sets of labels and verify that all three sets were counted accurately.\nMake sure you write a protocol for that and approve it before you start any testing period","book":"internal_audit_report_2024"}
{"chunk":"record the results in the protocol and then write a final report once you've executed the\nprotocol to summarize the results. Once you have all those reports completed, validation\nis considered complete, and you should be fine after that.\nWith regard to the label room access, review the list that we had printed out and distill","book":"internal_audit_report_2024"}
{"chunk":"that down to only those people that actually need access to that room. That should be no\nmore than three to four people at most. Remember, just because someone is a manager\nor officer of the company does not mean they automatically get access. Guard those labels\nlike you would guard controlled substances.\nObservation 2 (Major).","book":"internal_audit_report_2024"}
{"chunk":"Vendor Qualifications\nYour vendor qualification process is going to need some work. Step one, categorize your\nvendors as category 1, 2 or 3. Category 1 suppliers have direct impact on the product,\nwhich means these suppliers provide you with materials that go directly into, or touch","book":"internal_audit_report_2024"}
{"chunk":"the product. Category 2 suppliers are those suppliers that provide materials that do not\ngo directly into the product but are used in the manufacture of your products. An\nexample of a category 2 supplier would be a supplier who provides secondary packaging.\nCategory 3 suppliers our suppliers that provide everything else that does not go into the","book":"internal_audit_report_2024"}
{"chunk":"manufacturer of the product. Example of a category 3 supplier would be a supplier who\nprovides janitorial services for the office.\nThe next step is to decide how you're going to qualify each of the categories of suppliers.\nCategory 1 suppliers typically are qualified by an on-site audit of the facility and","book":"internal_audit_report_2024"}
{"chunk":"manufacturing process. Category 2 suppliers can be an audit, but is typically done\nPage 9\nRECOMMENDATIONS FOR IMPROVEMENT\nthrough some type of survey that is sent to the supplier that they complete and send\nback. Oftentimes you can also ask for certificates such as ISO certificates. Once you've","book":"internal_audit_report_2024"}
{"chunk":"categorized the suppliers, and determined how you're going to qualify each category of\nsupplier, the next step is to perform the qualifications as per your SOP.\nObservation 3 (Minor).\nRecords and Reports\nProduction equipment settings should be transferred into the master batch record directly","book":"internal_audit_report_2024"}
{"chunk":"from the validation protocol. For example, when the mixer was qualified using a protocol\nas you were incrementally increasing RPMs on the mixer, there should have been a setting\nwhere the batch would begin properly mix. As the RPMS continued to increased\nincrementally, you would eventually reach an upper limit where the batch was no longer","book":"internal_audit_report_2024"}
{"chunk":"in specification, or you reached the upper equipment capability limit. So, the operating\nrange would then be the lower limit where the batch first came into specification and the\nupper limit would be where the batch started to go out of specification. Typically, you","book":"internal_audit_report_2024"}
{"chunk":"would increase 10% above the lower limit and decrease 10% below the upper limit to give\nyourself a buffer from the actual limits.\nObservation 4 (Minor).\nFacilities\nAs I mentioned previously, flying insect light traps are an integral part of a good pest\ncontrol program. When you look for these on the market for purchase, be sure you're","book":"internal_audit_report_2024"}
{"chunk":"getting a light trap and not a bug zapper. The difference between the two being that an\ninsect trap uses UV lights with a glue board behind it, where the insects stick to the glue\nboard. A bug zapper, which is what I\u2019m sure most of you are familiar with, is a device that","book":"internal_audit_report_2024"}
{"chunk":"has a light that attracts the insect and then an electrical circuit that electrocutes the insect\nonce it makes contact with it. You don't want this because it will cause more\ncontamination from exploding insects that fly into the device. So be sure you get a light\ntrap and not a zapper.\nPage 10\nRECOMMENDATIONS FOR IMPROVEMENT","book":"internal_audit_report_2024"}
{"chunk":"The other key part to installing these devices is to be sure that wherever it is installed it is\nnot visible from the outside at night. An example would be you would not want to install it\non a wall where you could see through an exterior window from the outside and see the","book":"internal_audit_report_2024"}
{"chunk":"light trap on the inside. This attracts bugs to your building, so be sure that the light traps\nare not visible from the outside so that you don't attract bugs towards the building. These\ntraps should only be catching those pests that penetrate the building when doors are open","book":"internal_audit_report_2024"}
{"chunk":"such as a dock door or an entryway. Consult with your pest control company as to where\nthe best location for these devices would be, but also be mindful that it is positioned as I\noutlined as not all pest control companies may know this tip.\nPage 11\nSUMMARY\nSummary","book":"internal_audit_report_2024"}
{"chunk":"SUMMARY\nSummary\nMy overall impression at the end of the audit was that the quality system is appropriate\nfor the size of the organization, and the staff are very well trained and working in a way\nthat is compliant with current good manufacturing practices.\nIn total there were four observations, some with multiple parts. The observations were","book":"internal_audit_report_2024"}
{"chunk":"significant, especially the labeling observations, which if not corrected could result in\nproduct mislabeling. Mislabeling is the number one issue leading to recalls. All\nobservations should be corrected as soon as possible as each area can have a significant\nimpact on product quality.","book":"internal_audit_report_2024"}
